|
Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis Clinical research trials and Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis. Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis clinical trial. Test subjects typically receive the most effective healthcare possible for their Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis  Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis
Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis
For Condition: Liver Cirrhosis, Biliary
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) , National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),University of Texas
Synopsis: OBJECTIVES: I. Compare the effects of ursodiol (ursodeoxycholic acid), with and without methotrexate, on pruritus, incapacitation index, and serum markers of activity and severity in patients with primary biliary cirrhosis. II. Compare the effects of these regimens on the development of ascites, encephalopathy, varices (or bleeding from pre-existing varices), histologic liver changes, transplantation, and survival. III. Compare the toxicity and safety of each regimen.
Details: PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution and Ludwig histologic stage. All patients are treated with ursodiol (ursodeoxycholic acid, UDCA) for 6 months. If entry criteria continue to be met, patients are randomly assigned to UDCA/methotrexate or UDCA/placebo. Combination therapy continues for at least 5 years.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind
Minimum Age/Maximum Age: 20 Years/69 Years
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- The following criteria must be met prior to study entry and ursodiol treatment: Bilirubin less than 3 mg/dL Alkaline phosphatase at least 1.5 times normal limits Albumin at least 3 g/dL The following criteria must be met prior to randomization to Arms I and II: Primary biliary cirrhosis (PBC), i.e.: Cholestatic liver disease for at least 6 months prior to randomization Liver biopsy compatible with PBC within 6 months prior to randomization No biliary obstruction on ultrasound, computerized tomography, or cholangiography The following exclude: Asymptomatic and stage I liver histology (Ludwig classification) Hepatic encephalopathy Ascites Variceal bleeding No liver disease of other etiology, e.g.: Chronic hepatitis B or C Autoimmune chronic active hepatitis Alcoholic liver disease Sclerosing cholangitis Drug-induced liver disease Symptomatic or obstructive gallstones --Prior/Concurrent Therapy-- At least 6 months since the following immunosuppressives: Cyclosporine Tacrolimus Methotrexate At least 3 months since other immunosuppressives, e.g.: Azathioprine Chlorambucil Colchicine Corticosteroids Penicillamine At least 3 months since rifampin --Patient Characteristics-- Life expectancy: No major illness limiting life span Hematopoietic: WBC at least 2500/mm3 Absolute granulocyte count at least 1500/mm3 Platelet count at least 80,000/mm3 Hepatic: See Disease Characteristics Renal: Creatinine clearance at least 60 mL/min Pulmonary: No diffusion capacity or vital capacity less than 50% of predicted Other: Antimitochondrial antibody positive HIV antibody negative No alcoholism within the past 2 years No epilepsy requiring phenytoin No malignancy within the past 5 years other than skin cancer No pregnant women Adequate contraception required of fertile patients
Total Enrollment: 315
Location and Contact Information:
Overall Study Official:
BurtonCombes, Study Chair, University of Texas
Additional Information:
Study ID Numbers: 199/11873; UTSMC-29205400
Study Start Date: January 1994
Record last reviewed: December 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004784
Other Liver Cirrhosis, Biliary Studies:
1. Ursodiol-Methotrexate for Primary Biliary Cirrhosis
2. Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis
3. Pilot Study of Budesonide for Patients with Primary Sclerosing Cholangitis
4. Low-Dose Oral Methotrexate versus Colchicine for Primary Biliary Cirrhosis
5. Treatment of Cholestatic Pruritus With Sertraline
Related Studies:
Other Liver Cirrhosis, Biliary Clinical Trials
Other Clinical Trials
Other Clinical Trials
Phase III Randomized Study of Ursodiol with vs without Methotrexate for Primary Biliary Cirrhosis
|
|
|
|
|
|
|
|
